16.12
Schlusskurs vom Vortag:
$16.70
Offen:
$16.58
24-Stunden-Volumen:
1.88M
Relative Volume:
1.42
Marktkapitalisierung:
$2.81B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-382.71M
KGV:
-6.1527
EPS:
-2.62
Netto-Cashflow:
$-325.64M
1W Leistung:
+8.77%
1M Leistung:
+0.19%
6M Leistung:
-12.82%
1J Leistung:
-47.47%
Immunovant Inc Stock (IMVT) Company Profile
Firmenname
Immunovant Inc
Sektor
Branche
Telefon
917-580-3099
Adresse
320 WEST 37TH STREET, NEW YORK, NY
Vergleichen Sie IMVT mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
IMVT
Immunovant Inc
|
16.12 | 2.63B | 0 | -382.71M | -325.64M | -2.62 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-07-10 | Fortgesetzt | Goldman | Neutral |
2025-03-03 | Eingeleitet | Jefferies | Hold |
2025-01-03 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
2024-10-10 | Fortgesetzt | Raymond James | Outperform |
2024-10-09 | Bestätigt | Oppenheimer | Outperform |
2024-03-28 | Eingeleitet | Oppenheimer | Outperform |
2024-03-13 | Eingeleitet | Goldman | Buy |
2024-02-20 | Eingeleitet | JP Morgan | Overweight |
2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
2023-10-13 | Hochstufung | UBS | Neutral → Buy |
2023-09-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
2023-05-01 | Eingeleitet | BofA Securities | Buy |
2023-04-25 | Eingeleitet | Citigroup | Buy |
2023-03-31 | Eingeleitet | Piper Sandler | Overweight |
2023-03-30 | Eingeleitet | Stifel | Buy |
2023-02-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
2023-02-13 | Hochstufung | Guggenheim | Neutral → Buy |
2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2022-09-26 | Herabstufung | UBS | Buy → Neutral |
2021-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
2021-08-03 | Herabstufung | Robert W. Baird | Outperform → Neutral |
2021-08-02 | Herabstufung | Credit Suisse | Neutral → Underperform |
2021-06-01 | Herabstufung | Guggenheim | Buy → Neutral |
2021-06-01 | Herabstufung | Stifel | Buy → Hold |
2020-10-28 | Eingeleitet | UBS | Buy |
2020-10-12 | Eingeleitet | Guggenheim | Buy |
2020-10-08 | Eingeleitet | Stifel | Buy |
2020-10-02 | Eingeleitet | Credit Suisse | Outperform |
2020-08-26 | Bestätigt | H.C. Wainwright | Buy |
2020-08-25 | Eingeleitet | Raymond James | Outperform |
2020-07-29 | Eingeleitet | H.C. Wainwright | Buy |
2020-02-24 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Immunovant Inc Aktie (IMVT) Neueste Nachrichten
Earnings visualization tools for Immunovant Inc.Market Activity Summary & Consistent Income Trade Recommendations - Newser
Is Immunovant Inc. trending in predictive chart modelsJuly 2025 Levels & Weekly Return Optimization Alerts - Newser
Immunovant reports promising remission data for Graves’ disease therapy By Investing.com - Investing.com Australia
What is Immunovant Inc.’s book value per shareJuly 2025 Update & Daily Volume Surge Trade Alerts - khodrobank.com
Batoclimab data in Graves’ could signal bigger Immunovant win - BioWorld MedTech
Immunovant’s Batoclimab: A Game-Changer in the Evolving Graves’ Disease Market - AInvest
IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results - TradingView
Momentum divergence signals in Immunovant Inc. chart2025 Buyback Activity & AI Enhanced Trading Alerts - Newser
Is Immunovant Inc. a strong growth stockMarket Volume Summary & Consistent Income Trade Recommendations - khodrobank.com
What machine learning models say about Immunovant Inc.2025 Market Trends & Verified Entry Point Detection - Newser
Immunovant stock rises as Oppenheimer reiterates Outperform on Graves’ data - Investing.com
Real time social sentiment graph for Immunovant Inc.Entry Point & Long-Term Safe Return Strategies - Newser
What institutional flow reveals about Immunovant Inc.Market Trend Report & AI Optimized Trading Strategy Guides - Newser
Combining price and volume data for Immunovant Inc.July 2025 Outlook & Reliable Intraday Trade Plans - Newser
Why Immunovant Stock Blasted Higher Today - AOL.com
Can momentum traders help lift Immunovant Inc.Portfolio Return Report & Verified Chart Pattern Trade Signals - Newser
Why Immunovant Stock Blasted Higher Today - The Motley Fool
Immunovant Reports 'Encouraging' Data on Graves' Disease Treatment; Shares Rise - MarketScreener
What to expect from Immunovant Inc. in the next 30 daysQuarterly Performance Summary & Fast Entry and Exit Trade Plans - Newser
Immunovant Data for Batoclimab Shows Potential for Treating Uncontrolled Graves' Disease - MarketScreener
Immunovant Announces Promising Graves’ Disease Study Results - TipRanks
Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients - The Manila Times
Immunovant reports promising remission data for Graves’ disease therapy - Investing.com
Immunovant Reports Promising Six-Month Off-Treatment Data for Batoclimab in Uncontrolled Graves' Disease Patients - Quiver Quantitative
Immunovant Announces Promising Six-Month Follow-Up Data for Batoclimab in Uncontrolled Graves’ Disease Patients, Potentially Disease-Modifying Therapy - Quiver Quantitative
80% of Patients Maintain Normal Thyroid Function: Immunovant's Breakthrough in Graves' Disease Treatment Study - Stock Titan
Using data tools to time your Immunovant Inc. exit2025 Big Picture & Low Risk Entry Point Tips - Newser
Visual analytics tools that track Immunovant Inc. performanceJuly 2025 Sentiment & Community Verified Trade Alerts - Newser
Intraday pattern recognizer results for Immunovant Inc.Market Activity Summary & Real-Time Stock Price Movement Reports - Newser
Using RSI to spot recovery in Immunovant Inc.M&A Rumor & Consistent Growth Stock Picks - Newser
Volume spikes in Immunovant Inc. stock – what they meanRisk Management & Advanced Technical Signal Analysis - Newser
How to use a screener to detect Immunovant Inc. breakoutsJuly 2025 Rallies & Stepwise Trade Signal Implementation - Newser
Applying Elliott Wave Theory to Immunovant Inc.July 2025 Update & Verified Momentum Watchlists - Newser
Immunovant Inc. stock volume spike explainedWeekly Gains Summary & Growth Oriented Trading Recommendations - Newser
Is now a turning point for Immunovant Inc.2025 Risk Factors & Free Fast Entry Momentum Trade Alerts - Newser
Is Immunovant Inc. stock entering bullish territoryQuarterly Earnings Report & Fast Exit/Entry Strategy Plans - Newser
Real time breakdown of Immunovant Inc. stock performanceCPI Data & Fast Gaining Stock Strategy Reports - Newser
What indicators show strength in Immunovant Inc.Quarterly Earnings Report & Weekly Watchlist for Hot Stocks - Newser
Using economic indicators to assess Immunovant Inc. potentialMarket Risk Report & Low Risk High Win Rate Stock Picks - Newser
Immunovant Inc. stock outlook for YEARJuly 2025 Review & Fast Gaining Stock Reports - Newser
Is Immunovant Inc. stock poised for growthMarket Movement Recap & Free Weekly Watchlist of Top Performers - Newser
Long term hold vs stop loss in Immunovant Inc.Layoff News & Expert Approved Momentum Trade Ideas - Newser
What’s next for Immunovant Inc. stockJuly 2025 Analyst Calls & Free High Return Stock Watch Alerts - khodrobank.com
Short interest data insights for Immunovant Inc.July 2025 Patterns & Fast Entry and Exit Trade Plans - Newser
Immunovant Inc. stock trend outlook and recovery pathPortfolio Value Summary & Low Volatility Stock Suggestions - Newser
Should you avoid Immunovant Inc. stock right nowJuly 2025 Update & Advanced Swing Trade Entry Alerts - khodrobank.com
Regression analysis insights on Immunovant Inc. performanceQuarterly Profit Review & Expert Approved Momentum Ideas - Newser
Published on: 2025-09-01 10:52:28 - Newser
Is Immunovant Inc. a play on infrastructure spendingTrend Reversal & Safe Entry Zone Tips - khodrobank.com
Finanzdaten der Immunovant Inc-Aktie (IMVT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immunovant Inc-Aktie (IMVT) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Geffner Michael | Chief Medical Officer |
Jul 23 '25 |
Sale |
18.15 |
2,385 |
43,288 |
221,825 |
Geffner Michael | Chief Medical Officer |
Jul 09 '25 |
Sale |
17.24 |
1,160 |
19,998 |
224,210 |
Stout Jay S | Chief Technology Officer |
Jul 09 '25 |
Sale |
17.24 |
1,519 |
26,188 |
207,724 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):